Monitor for initiation of the ART26.12 multiple ascending dose study in Q4 2026, which is the next major catalyst. The $4.2M cash position suggests a need for additional financing within the next 6-12 months, likely via dilutive offering. No analyst consensus exists for this micro-cap, so price action will be driven by pipeline updates and capital markets activity.
Price Chart
Executive Summary
Artelo Biosciences reported Q2 2026 net loss of $2.4M ($0.89/share) vs $3.2M in Q2 2025, with R&D expenses halved to $0.9M. The company highlighted progress in its ART26.12 program toward a Phase 1 multiple ascending dose study in Q4 2026 and completed an $11.0M financing to extend its cash runway. With only $4.2M in cash and no revenue, the stock remains a binary option on clinical catalysts for a micro-cap biotech.
Key Financial Metrics
Key Facts
- Net loss narrowed to $2.4M ($0.89/share) from $3.2M in Q2 2025
- R&D expenses fell to $0.9M from $1.9M year-over-year
- Cash and investments totaled $4.2M as of June 30, 2026
- Completed $11.0M financing to strengthen balance sheet
- ART26.12 Phase 1 multiple ascending dose study expected to start in Q4 2026
- No revenue reported; pre-revenue clinical-stage company
Financial Impact
Net loss of $2.4M in Q2 2026, down from $3.2M in Q2 2025; cash burn rate implies runway of approximately 2-3 quarters at current spend
Risk Factors
- Cash runway limited to approximately 2-3 quarters at current burn rate, requiring additional financing
- Pre-revenue clinical-stage biotech with no approved products; binary risk on pipeline outcomes
- Stock has $3M market cap and minimal institutional ownership, making it highly volatile and illiquid
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3344440 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 9, 2026 16d ago | 8-K | $3.11 | awaiting T+60 | — | $2.36 (+24.28%) |
Sep 16, 2026 5w ago | Press Release | $3.75 | awaiting T+60 | — | $2.36 (−37.20%) |
Aug 13, 2026 10w ago | Press Release | $6.83 | awaiting T+60 | — | $2.36 (−65.52%) |
Jul 16, 2026 14w ago | DEFA14A | $1.14 $0.3622 | ▼ −68.23% | ▼ −71.94% | $2.36 (+106.58%) |
Jul 16, 2026 14w ago | Press Release | $1.14 $0.3622 | ▼ −68.23% | ▼ −71.94% | $2.36 (+106.58%) |
Jul 13, 2026 15w ago | Press Release | $1.05 $0.3844 | ▼ −63.39% | ▼ −67.38% | $2.36 (+124.29%) |
Jul 2, 2026 16w ago | DEFA14A | $1.11 $0.4522 | ▲ +59.26% | ▲ +60.98% | $2.36 (−112.16%) |
May 27, 2026 21w ago | 8-K | $1.46 $0.6920 | ▲ +52.60% | ▲ +54.34% | $2.36 (−61.30%) |
May 18, 2026 22w ago | 424B5 | $1.36 $0.7587 | ▼ −44.21% | ▼ −50.50% | $2.36 (+73.16%) |
May 15, 2026 23w ago | 8-K | $1.46 $0.7330 | ▼ −49.79% | ▼ −54.65% | $2.36 (+61.30%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers